Regulation of Pathogenic Plasma Cells in Human SLE

新冠肺炎新的免疫诊断方法对急性感染、重症预后和 感染的消退。 正在蔓延的新冠肺炎疫情再次突显了开发更好的诊断测试和 疫苗旨在通过以下途径增强有效的B细胞反应和被动治疗 注射中和单抗。我们的应用程序，将直接解决 新的免疫分析方法可以诊断急性新冠肺炎感染，为可能发生感染的患者提供预后 严重呼吸道并发症，并确定无症状成年人的免疫力和疾病解决 这场大流行的进程。 我们的实验室在B细胞和浆细胞对疫苗和流感病毒感染的反应方面拥有专业知识 为一种新的诊断平台提供基础，该平台在以下情况下询问循环抗体分泌细胞(ASC) 一位病人病了。这项技术可以诊断以下微生物感染：流感病毒，呼吸道 合胞病毒(RSV)1、2、肺炎链球菌、金黄色葡萄球菌 、艰难梭状芽胞杆菌(Clostridioidesfficile) (Haddad等人，在回顾中)和伯氏疏螺旋体(莱姆病)。最初是用新鲜血液ASC在 繁琐的Elispot免疫分析，Microb-plex，Inc.的戴斯和李博士将这种分析简化为 一种专利技术，利用从分离的血液ASC中新分泌的抗体的培养上清液。 新的基质是Mensa，一种“富含新合成抗体的介质”，可以很容易地进行多路复用 含有超过10-12个抗原(如初步数据所示)。可以很容易地收集无细胞门萨基质并 冷冻，以评估患病时的同期ASC反应。此外，消极的门萨 确诊后可显示病毒的清除和主动免疫反应的消退。在这 作为补充，我们建议建立一种新的基于免疫的新冠肺炎门萨试验(1)来诊断急性白血病 感染和(2)以及预测有呼吸衰竭风险的患者。此外，通过决议 感染，新冠肺炎门萨阴性，血清试验阳性，表明对疾病有免疫力 决议。所有测试都将可用于商业化，而不需要为这种COVID19大流行专门发放许可证。

Novel Immune Diagnostics of COVID-19 for Acute Infection, Prognosis of Severe Disease, and Resolution of Infection. The spreading COVID-19 pandemic has once again highlighted the need to develop better diagnostic tests and vaccines geared towards the enhancement of effective B cell responses and passive therapies through the administration of neutralizing monoclonal antibodies. Our application, will directly address the development of novel immune assays to diagnose acute COVID-19 infection, provide prognosis of patients who may develop severe respiratory complications, and identify immunity and disease resolution in asymptomatic adults during the course of this pandemic. Our laboratories with expertise in B cells and plasma cell responses to vaccines and influenza virus infections provide the basis for a novel diagnostic platform that interrogates circulating antibody secreting cells (ASC) when a patient is ill. This technology can diagnose the following microbial infections: Influenza virus, Respiratory syncytial virus (RSV) 1,2, Streptococcus pneumoniae, Staphylococcus aureus 3 , Clostridioides difficile (C. difficile) (Haddad et al, in review), and Borrelia burgdorferi (Lyme disease). Originally performed with fresh blood ASC in cumbersome Elispot immunoassays, Drs. Daiss and Lee at MicroB-plex, Inc. have streamlined the assay into a patented technology that utilizes a cultured supernatant of newly secreted antibodies from isolated blood ASC. The novel matrix is MENSA, a “media enriched with newly synthesized antibodies” and can be easily multiplexed with over 10-12 antigens (as shown in preliminary data). The cell free-MENSA matrix can be easily collected and frozen to evaluate the contemporaneous ASC responses at the time of illness. In addition, a negative MENSA after diagnosis can demonstrate viral clearance and resolution of the active immune response. In this supplement, we propose to develop a novel immune-based COVID-19 MENSA assay (1) to diagnose acute infection and (2) and to prognosticate patients at risk of respiratory failure. In addition, with resolution of infection, a negative COVID-19 MENSA and positive serum test will show immunity with disease resolution. All tests will be available for commercialization without a need for licensing specific for this COVID19 pandemic.